<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03604965</url>
  </required_header>
  <id_info>
    <org_study_id>201805043</org_study_id>
    <nct_id>NCT03604965</nct_id>
  </id_info>
  <brief_title>GP Induction Chemotherapy us TPF Adjuvant Chemotherapy Combined With DDP Concurrent Chemoradiotherapy in the Treatment of Locally Advanced NPC</brief_title>
  <official_title>A Multicenter, Randomized Controlled Phase III Clinical Trial of GP Induction Chemotherapy With TPF Adjuvant Chemotherapy Combined With DDP Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guiyang Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guiyang Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Through randomized controlled phase III multicenter clinical trials, GP induction
      chemotherapy vs TPF regimen adjuvant chemotherapy combined with DDP concurrent
      chemoradiotherapy for the treatment of locally advanced nasopharyngeal carcinoma: the
      efficacy, toxicity and quality of life, and further improvement Survival rate and improve the
      quality of life.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">July 21, 2018</start_date>
  <completion_date type="Anticipated">July 21, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 21, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progress-free survival(PFS)</measure>
    <time_frame>3 years</time_frame>
    <description>Progress-free survival(year) is calculated from the date of randomization to the date of the first progress at any site or death from any cause or censored at the date of the last follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival(OS)</measure>
    <time_frame>3 years</time_frame>
    <description>The OS(year) was defined as the duration from the date of random assignment to the date of death from any cause or censored at the date of the last follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Locoregional failure-free survival(LRFS)</measure>
    <time_frame>3 years</time_frame>
    <description>The LRFS(year) is evaluated and calculated from the date of random assignment until the day of first locoregional relapse or until the date of the last follow-up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant metastasis-free survival(DMFS)</measure>
    <time_frame>3 years</time_frame>
    <description>The DMFS(year) is evaluated and calculated from the date of random assignment until the day of first distant metastases or until the date of the last follow-up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>3 years</time_frame>
    <description>Tumour response(CR/PR/SD/PD) was classified according to RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute and late toxicity</measure>
    <time_frame>3 years</time_frame>
    <description>Incidence of acute toxicity（Grade1/2/3/4） is calculated for each adverse event respectively and severity is evaluated on basis of Common Terminology Criteria for Adverse Events (CTCAE) 4.0 criteria. Late radiation toxicities were assessed using the Radiation Therapy Oncology Group and European Organization for Research and Treatment of Cancer late radiation morbidity scoring scheme</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">204</enrollment>
  <condition>Locally Advanced Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>GP+CCRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GP neoadjuvant chemotherapy followed by cisplatin chemotherapy concurrent combined with intensity-modulated radiation therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TPF+CCRT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TPF neoadjuvant chemotherapy followed by cisplatin chemotherapy concurrent combined with intensity-modulated radiation therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GP+CCRT</intervention_name>
    <description>Patients receive Neoadjuvant gemcitabine (1000mg/m2 on day1 and day8 ) and cisplatin (80mg/m2 on day1)every 21days for three cycles followed by concurrent cisplatin (100mg/m2 on day1 or day2)every 21 days for three cycles during radiotherapy</description>
    <arm_group_label>GP+CCRT</arm_group_label>
    <other_name>Experimental group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TPF+CCRT</intervention_name>
    <description>Patients receive Neoadjuvant Docetaxel (75mg/m2 on day1 03:30-04:30) and cisplatin (75mg/m2 on day 1-5 10:00-22:00) and 5-FU(750mg/m2 on day 1-5 22:00-10:00) every 21days for three cycles followed by concurrent cisplatin (100mg/m2 on day1 or day2)every 21 days for three cycles during radiotherapy</description>
    <arm_group_label>TPF+CCRT</arm_group_label>
    <other_name>Control group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. In the newly diagnosed patient, no radiotherapy or chemotherapy was performed before
             the start of the clinical trial.

          2. Pathologically confirmed as non-keratinizing nasopharyngeal carcinoma (differentiated
             or undifferentiated, ie WHO type II or III).

          3. III, IVa patients (AJCC version 8 staging).

          4. Male or non-pregnant women.

          5. Age ≥ 18 and &lt; 70 years old.

          6. Functional status: Karnofsky scale (KPS) &gt; 70.

          7. White blood cells (WBC) ≥ 4 × 109.

             /L, hemoglobin (HGB) ≥ 90 g / L, platelets (PLT) ≥ 100 × 109 / L (or within the normal
             range of the laboratory)

          8. Liver function: alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤ 1.5
             times the upper limit of normal (ULN); Total bilirubin ≤ 1.5 × ULN.

          9. Renal function: creatinine clearance ≥ 60ml / min or serum creatinine ≤ 1.5 × ULN.

         10. The patient has signed an informed consent form.

        Exclusion Criteria:

          1. The pathological type is WHO's keratinized squamous cell carcinoma or basal squamous
             cell carcinoma.

          2. Age ≥ 70 years old or &lt; 18 years old.

          3. Treatment is palliative.

          4. Previous history of malignant tumors, well-treated basal cell carcinoma or squamous
             cell carcinoma and cervical carcinoma in situ outer.

          5. Women during pregnancy or lactation (pregnant women should be considered for women of
             childbearing age; Effective contraception).

          6. Previously received radiation therapy (if non-melanoma skin cancer and previous
             lesions are outside the target area of radiotherapy, then except).

          7. Primary and cervical metastatic lesions received chemotherapy or surgery (except for
             diagnostic treatment).

          8. With other serious diseases, it may bring greater risk or affect the compliance of the
             test. For example: no need for treatment Stable heart disease, kidney disease, chronic
             hepatitis, control of unsatisfactory diabetes (fasting blood glucose &gt; 1.5 × ULN),And
             mental illness.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuanyuan Li, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guizhou Provincial Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Feng Jin, Bachelor</last_name>
    <phone>0851-86512802</phone>
    <email>jinf8865@yeah.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuanyuan Li, Master</last_name>
    <phone>0851-86512802</phone>
    <email>lilyuanyuan@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer Hospital of Guizhou Medical University</name>
      <address>
        <city>Guiyang</city>
        <state>贵州省</state>
        <zip>550000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuanyuan Li, master</last_name>
      <phone>085186512802</phone>
      <email>lilyuanyuan@qq.com</email>
    </contact>
    <investigator>
      <last_name>Feng Jin, Bachelor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Weili Wu, Master</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jinhua Long, Master</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiuling Luo, Bachelor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiuyun Gong, Bachelor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yanfang Cen, Bachelor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 21, 2018</study_first_submitted>
  <study_first_submitted_qc>July 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2018</study_first_posted>
  <last_update_submitted>July 21, 2018</last_update_submitted>
  <last_update_submitted_qc>July 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guiyang Medical University</investigator_affiliation>
    <investigator_full_name>Feng Jing</investigator_full_name>
    <investigator_title>Head and neck cancer director, chief researcher, clinical professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

